uniQure Shares Collapse Following Disappointing Clinical Trial Results

Key Facts

uniQure shares experienced a sharp decline in today's trading due to negative market reaction. Investing.com reported that the sell-off followed the release of clinical data or pipeline updates that failed to meet investor expectations.

QURE closed at $39.11 on September 28, 2026, prior to the significant downward pressure in the subsequent session. The collapse has led to a loss of investor confidence in the company's short-term valuation following the disappointing developments in its clinical programs.